

A Double Blind Placebo Controlled Clinical Trial for the Treatment of Psychosis in Individuals with Velo-Cardio-Facial Syndrome

Individuals who have velo-cardio-facial syndrome (also known as VCFS, 22q11 deletion syndrome, DiGeorge syndrome, and Shprintzen syndrome) and who are currently experiencing psychiatric illness including schizophrenia, bipolar psychosis, schizoaffective disorder, mood disorder with psychotic features, or psychosis NOS may be candidates for a clinical trial designed to assess the safety and effectiveness of an FDA approved drug for the treatment of their psychosis. Study subjects must be between 16 and 65 years of age and have an IQ score of at least 50. There are several other qualifications for the study that will be explained in detail for those interested in participating. For details about qualifications for the study, please contact the study's principal investigator, Dr. Robert Shprintzen, or the study coordinator, Anne Marie Higgins, R.N., F.N.P., M.A. by telephone at 315-464-6590, 315-464-6597, 315-464-6595, by fax at 315-464-6598, or by email at vcfs@upstate.edu.